Brancaster Pharma

Brancaster Pharma is a UK-based specialty pharmaceutical company that focuses on the acquisition, development, and commercialization of niche, off-patent, and hard-to-source medicines. Founded in 2014, the company specializes in identifying essential medications that are difficult to source or require specific regulatory expertise to maintain in the market. In May 2017, Brancaster Pharma was acquired by Advanz Pharma (formerly Concordia International), which integrated Brancaster's portfolio into its broader specialty medicine offerings. The company's business model centers on regulatory expertise and supply chain management for established therapeutic products. Its operations are primarily focused on ensuring the supply of critical medicines to the National Health Service (NHS) and other European healthcare systems.